

Carlo Sposito

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3485233/publications.pdf>

Version: 2024-02-01

65
papers

4,069
citations

249298

26
h-index

139680

61
g-index

65
all docs

65
docs citations

65
times ranked

5182
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of lymphadenectomy in the surgical treatment of intrahepatic cholangiocarcinoma: A review. <i>European Journal of Surgical Oncology</i> , 2022, 48, 150-159.	0.5	19
2	Is minimally invasive liver surgery a reasonable option in recurrent HCC? A snapshot from the I Go MILS registry. <i>Updates in Surgery</i> , 2022, 74, 87-96.	0.9	10
3	Long Term Survival Analysis in a Cohort of 125 Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using Small Drug Eluting Beads. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 54-61.	0.9	0
4	Impact of Surgical Margins on Overall Survival after Gastrectomy for Gastric Cancer: A Validation of Japanese Gastric Cancer Association Guidelines on a Western Series. <i>Annals of Surgical Oncology</i> , 2022, 29, 3096-3108.	0.7	10
5	ASO Visual Abstract: Impact of Surgical Margins on Overall Survival After Gastrectomy for Gastric Cancer: A Validation of Japanese Gastric Cancer Association Guidelines on a Western Series. <i>Annals of Surgical Oncology</i> , 2022, 29, 3111.	0.7	1
6	ASO Author Reflections: Less is more: Organ-Sparing Approach for the Surgical Treatment of Gastric Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2022, 29, 3109-3110.	0.7	1
7	Preoperative predictors of liver decompensation after mini-invasive liver resection. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 718-727.	1.3	10
8	Resection of Retro-Hepatic Vena Cava (RHVC) En-bloc with Caudate Lobe without Vascular Exclusion for a Low Grade Leiomyosarcoma of Inferior Vena Cava. <i>Annals of Surgical Oncology</i> , 2021, 28, 6848-6849.	0.7	3
9	Transplantation of autologous extracellular vesicles for cancer-specific targeting. <i>Theranostics</i> , 2021, 11, 2034-2047.	4.6	32
10	Liver resection for perihilar cholangiocarcinoma: Impact of biliary drainage failure on postoperative outcome. Results of an Italian multicenter study. <i>Surgery</i> , 2021, 170, 383-389.	1.0	10
11	Improved management of grade B biliary leaks after complex liver resections using gadoxetic acid disodium-enhanced magnetic resonance cholangiography. <i>Surgery</i> , 2021, 170, 499-506.	1.0	2
12	Postrecurrence Survival After Liver Transplantation for Liver Metastases From Neuroendocrine Tumors. <i>Transplantation</i> , 2021, 105, 2579-2586.	0.5	13
13	Tremellumab and Durvalumab Combination for the Non-Operative Management (NOM) of Microsatellite Instability (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. <i>Cancers</i> , 2021, 13, 2839.	1.7	31
14	Inter-center agreement of mRECIST in transplanted patients for hepatocellular carcinoma. <i>European Radiology</i> , 2021, 31, 8903-8912.	2.3	3
15	Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in Child-Pugh B cirrhosis. <i>Journal of Hepatology</i> , 2020, 72, 75-84.	1.8	105
16	A Combined Approach to Priorities of Surgical Oncology During the COVID-19 Epidemic. <i>Annals of Surgery</i> , 2020, 272, e84-e86.	2.1	16
17	Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 947-956.	5.1	166
18	Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant. <i>Journal of Hepatology</i> , 2020, 73, 342-348.	1.8	49

#	ARTICLE	IF	CITATIONS
19	Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials. <i>Oncologist</i> , 2020, 25, 780-786.	1.9	14
20	Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. <i>Clinical Colorectal Cancer</i> , 2020, 19, 156-164.	1.0	16
21	Assessing Competing Risks for Death Following Liver Transplantation for Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1001-1007.	1.1	11
22	Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable. <i>ESMO Open</i> , 2019, 4, e000496.	2.0	3
23	Permanent Pancreatic Duct Occlusion With Neoprene-based Glue Injection After Pancreatoduodenectomy at High Risk of Pancreatic Fistula. <i>Annals of Surgery</i> , 2019, 270, 791-798.	2.1	25
24	Multicenter validation of a score to predict prognosis after the development of HCC recurrence following liver transplantation. <i>Hpb</i> , 2019, 21, 731-738.	0.1	24
25	Relative Survival Instead of Overall Survival Should Be Used as Outcome When Analyzing the Effect of Age After Treatment of Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2018, 268, e76.	2.1	0
26	Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. <i>Journal of Hepatology</i> , 2018, 68, 724-732.	1.8	100
27	Reply to: "Validation of response to yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion". <i>Journal of Hepatology</i> , 2018, 69, 260-261.	1.8	1
28	Proposal of Prognostic Survival Models before and after Liver Resection for Hepatocellular Carcinoma in Potentially Transplantable Patients. <i>Journal of the American College of Surgeons</i> , 2018, 226, 1147-1159.	0.2	13
29	Pro (With Caution): Extended oncologic indications in liver transplantation. <i>Liver Transplantation</i> , 2018, 24, 98-103.	1.3	24
30	Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2018, 154, 128-139.	0.6	417
31	The SIRveNIB and SARAH trials, radioembolization vs. sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the future. <i>Hepatobiliary Surgery and Nutrition</i> , 2018, 7, 487-489.	0.7	39
32	Hepatocellular Carcinoma in Abernethy Malformation: A Rare Occurrence of Congenital Complete Portosystemic Shunt. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 1775-1778.	0.2	3
33	Liver Transplantation and Hepatic Resection can Achieve Cure for Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2018, 268, 868-875.	2.1	127
34	Reply. <i>Gastroenterology</i> , 2018, 154, 2276-2277.	0.6	1
35	Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis. <i>Digestive and Liver Disease</i> , 2018, 50, 1105-1114.	0.4	41
36	Development and validation of a survival calculator for hepatocellular carcinoma patients undergoing liver transplantation: the Metroticket 2.0 model. <i>Journal of Hepatology</i> , 2017, 66, S14-S15.	1.8	0

#	ARTICLE	IF	CITATIONS
37	Average treatment effect of hepatic resection <i>versus</i> locoregional therapies for hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2017, 104, 1704-1712.	0.1	21
38	The place of liver transplantation in the treatment of hepatic metastases from neuroendocrine tumors: Pros and cons. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 473-483.	2.6	26
39	Competing risk analysis on outcome after hepatic resection of hepatocellular carcinoma in cirrhotic patients. <i>World Journal of Gastroenterology</i> , 2017, 23, 1469.	1.4	16
40	The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors. <i>American Journal of Transplantation</i> , 2016, 16, 2892-2902.	2.6	151
41	Propensity score analysis of outcomes following laparoscopic or open liver resection for hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2016, 103, 871-880.	0.1	130
42	Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma. <i>Liver International</i> , 2016, 36, 1033-1042.	1.9	28
43	Drug-eluting beads <i>versus</i> conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 645-653.	1.4	71
44	External validation of an individual prognostic calculator after transarterial chemoembolization for hepatocellular carcinoma. <i>Liver International</i> , 2016, 36, 1231-1231.	1.9	4
45	Liver transplantation for every early intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. <i>Hepatology</i> , 2016, 64, 1178-1188.	3.6	262
46	Effect of age on survival in patients undergoing resection of hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2016, 103, e93-e99.	0.1	53
47	Hierarchic Interaction of Factors Associated With Liver Decompensation After Resection for Hepatocellular Carcinoma. <i>JAMA Surgery</i> , 2016, 151, 846.	2.2	106
48	Development of a prognostic scoring system for resectable hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 8194.	1.4	7
49	Repeated transarterial chemoembolization: An overfitting effort?. <i>Journal of Hepatology</i> , 2015, 62, 1440-1442.	1.8	18
50	Radioembolization of hepatocarcinoma with 90Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1718-1738.	3.3	128
51	Transarterial Chemoembolization for Hepatocellular Carcinoma with a New Generation of Beads: Clinical Radiological Outcomes and Safety Profile. <i>CardioVascular and Interventional Radiology</i> , 2015, 38, 129-134.	0.9	59
52	Intrahepatic Flow Redistribution in Patients Treated with Radioembolization. <i>CardioVascular and Interventional Radiology</i> , 2015, 38, 322-328.	0.9	21
53	Reply to: "Time is a crucial factor for the use of oncological treatment for post-transplantation recurrence of hepatocellular carcinoma". <i>Journal of Hepatology</i> , 2014, 60, 230-231.	1.8	0
54	Reply to: "Sorafenib efficacy for treatment of HCC recurrence after liver transplantation is an open issue". <i>Journal of Hepatology</i> , 2014, 60, 682-683.	1.8	1

#	ARTICLE	IF	CITATIONS
55	A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the Liver Match study. <i>Digestive and Liver Disease</i> , 2014, 46, 340-347.	0.4	18
56	A Prospective Policy Development to Increase Split-Liver Transplantation for 2 Adult Recipients. <i>Annals of Surgery</i> , 2014, 259, 157-165.	2.1	53
57	Transhepatic anterior approach to the inferior vena cava in large retroperitoneal tumors resected en bloc with the right liver lobe. <i>Surgery</i> , 2013, 154, 1061-1068.	1.0	10
58	Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: A case-control study. <i>Journal of Hepatology</i> , 2013, 59, 59-66.	1.8	128
59	Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study. <i>Hepatology</i> , 2013, 57, 1826-1837.	3.6	428
60	Resection of hepatocellular cancer ≥ 2 cm: Results from two Western centers. <i>Hepatology</i> , 2013, 57, 1426-1435.	3.6	326
61	Milan criteria in liver transplantation for hepatocellular carcinoma: An evidence-based analysis of 15 years of experience. <i>Liver Transplantation</i> , 2011, 17, S44-S57.	1.3	471
62	The challenges of liver transplantation for hepatocellular carcinoma on cirrhosis. <i>Transplant International</i> , 2010, 23, 712-722.	0.8	45
63	Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: A proof of principle. <i>Journal of Hepatology</i> , 2010, 52, 771-775.	1.8	82
64	Portal Vein Arterialization for Hepatic Artery Thrombosis in Liver Transplantation: A Case Report, Doppler-Ultrasound Aspects, and Review of the Literature. <i>Transplantation Proceedings</i> , 2010, 42, 1369-1374.	0.3	12
65	Behaviour of the bowel wall during the first year after surgery is a strong predictor of symptomatic recurrence of Crohn's disease: a prospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 959-968.	1.9	54